The research team, led by Zheng Bi, Zhiyu Jiao, Ji Deng, and Taotao Bao of the Department of Endocrinology at the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine in Hefei, China, set out to bring order to a fragmented evidence base. Studies of MACS have been scattered across modern trials using current diagnostic criteria, older investigations framed around subclinical Cushing syndrome, nonrandomized cohort comparisons, and large database analyses. Because each of these study types carries different strengths and weaknesses, pooling them indiscriminately risks distorting the picture. The researchers therefore designed their synthesis to keep the evidence streams separate, analyzing randomized trial data, nonrandomized comparative cohorts, and database studies in distinct layers, and grouping linked reports by study cohort before any statistical combination took place.

The scale of the literature search was considerable. After removing duplicates, the team screened 1,089 records and assessed 21 full-text reports in detail, ultimately retaining 17 reports for the main or supporting synthesis. Those reports yielded 18 study-level or study-component rows: seven randomized reports or components of trial families, ten nonrandomized comparative cohort components, and one propensity-matched database study. Individual comparative sample sizes ranged from just 33 participants to as many as 582 participants or matched patients. Methodological rigor was built in from the start: risk of bias in randomized trials was evaluated with the Cochrane RoB 2 tool, nonrandomized studies were judged with ROBINS-I, and the certainty of each body of evidence was graded using the GRADE framework, which explicitly penalizes imprecision, inconsistency, and observational design.

The headline result concerns blood pressure. Across the randomized evidence, adrenalectomy was associated with substantially improved blood-pressure control, with a relative risk of 2.41 and a 95 percent confidence interval of 1.60 to 3.63, and with zero heterogeneity across studies, indicated by an I-squared of 0.0 percent. In practical terms, patients who had the affected adrenal gland removed were more than twice as likely to achieve improved blood-pressure outcomes compared with those managed conservatively, and the consistency across trials lent the finding moderate certainty under GRADE criteria. For a condition in which hypertension is one of the principal drivers of long-term cardiovascular harm, this is a clinically meaningful signal, suggesting that removing the source of cortisol excess can translate into measurable vascular benefit.

Metabolic outcomes told a similar, if slightly softer, story. The pooled randomized data showed that surgery was associated with improved glycometabolic control, with a relative risk of 3.40, a 95 percent confidence interval of 1.68 to 6.87, and again no statistical heterogeneity. Because the confidence interval, while excluding the null value, was wider than that for blood pressure and rested on fewer events, the authors assigned this outcome a low certainty rating, meaning further research could shift the estimate. Notably, when the analysis turned to objective ambulatory or 24-hour blood-pressure monitoring endpoints, a more precise and methodologically demanding way of capturing true blood-pressure burden, the effect shrank and lost statistical significance, with a relative risk of 1.57 and a confidence interval of 0.70 to 3.54 spanning unity. That discrepancy is a reminder that how an outcome is measured can shape what the evidence appears to show.

Adding a population-scale perspective, the single propensity-matched database study included in the review reported lower mortality and lower rates of new-onset diabetes among patients who underwent adrenalectomy. These are the hard outcomes that matter most to patients and clinicians alike, but the authors were careful to temper enthusiasm: the database evidence was rated as very low certainty under GRADE, reflecting the inherent limitations of observational claims in which unmeasured confounding can never be fully excluded. A database study can suggest that surgery might extend life or prevent diabetes, but it cannot prove it, particularly when the decision to operate is itself influenced by patient characteristics such as tumor size, hormone levels, surgical fitness, and patient preference.

The review also grappled with the less glamorous but crucially important question of surgical safety and the physiology of what happens after the operation. When one adrenal gland is removed in a patient whose other gland has been suppressed by years of autonomous cortisol production, the body can be left temporarily or sometimes permanently unable to produce adequate cortisol on its own, a state known as postoperative adrenal insufficiency. This condition is potentially life-threatening if unrecognized, requiring glucocorticoid replacement therapy and careful monitoring, often for months or longer. Because the included studies defined adrenal insufficiency inconsistently and used different reporting windows, the authors summarized these safety outcomes narratively rather than pooling them statistically, emphasizing that they are clinically important considerations in any shared decision about surgery.

What, then, should clinicians and patients take away from this synthesis? The authors conclude that adrenalectomy probably improves blood-pressure control and may improve glycometabolic outcomes in selected patients with unilateral MACS or closely related mild cortisol-autonomy phenotypes. The word selected carries weight: the trial evidence does not suggest that every person with an adrenal nodule and mildly elevated cortisol should head to the operating room. Operative risk, the burden of postoperative adrenal insufficiency, the need for lifelong vigilance about glucocorticoid dosing during illness, and individual patient values all belong in the calculus. For some patients, particularly those with poorly controlled hypertension or worsening metabolic disease attributable to cortisol excess, the surgical route now has firmer evidence behind it. For others, conservative management with targeted treatment of cardiovascular risk factors remains a defensible and often preferable course.

Equally important is what the review could not establish. Evidence for fracture prevention, mortality reduction, and other hard long-term outcomes remains insufficient for firm clinical conclusions, a gap the authors highlight as a priority for future research. MACS affects a meaningful proportion of the growing population of patients with adrenal incidentalomas, a finding that will only become more common as abdominal imaging continues to expand. Whether curing a subtle hormone excess ultimately prevents heart attacks, strokes, and broken bones is the question patients actually care about, and answering it will likely require large, well-designed prospective studies with long follow-up. Until then, this meta-analysis provides the clearest map yet of the terrain: surgery offers probable cardiovascular and possible metabolic benefits for carefully chosen patients, tempered by real operative and hormonal risks, and the field still awaits the definitive trial that settles the hardest questions once and for all.

Subject of Research: Systematic review and meta-analysis comparing adrenalectomy with conservative management in mild autonomous cortisol secretion

Article Title: Adrenalectomy versus conservative management in mild autonomous cortisol secretion: a systematic review and meta-analysis

Article References: Adrenalectomy versus conservative management in mild autonomous cortisol secretion: a systematic review and meta-analysis. (n.d.). https://doi.org/10.1186/s12902-026-02576-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02576-5

Keywords: mild autonomous cortisol secretion, adrenalectomy, adrenal incidentaloma, meta-analysis, blood pressure, diabetes, cortisol, conservative management, adrenal insufficiency, glucocorticoid replacement, systematic review, endocrinology